by Gus Iversen
, Editor in Chief | February 26, 2019
A new analysis from MEDraysintell, a market intelligence group specializing in radiotherapy and nuclear medicine, confirms that the high level of market activity seen in proton therapy during 2015 appears to have been an exception, not the norm, for investment in the cutting-edge cancer treatment.
The peak activity continued through mid-2016 when a slow decline began and continued throughout 2018. Last year's global investment in particle therapy (carbon as well as proton) was almost 20 percent lower than 2017, and 62 percent lower than 2015.
The report, called Proton Therapy World Market Report & Directory, Edition 2019, cites several factors contributing to the sluggish investment including negative publicity, resistance from health authorities and private insurances to reimburse proton therapy, and the overall cost hurdles of the treatment.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Proton therapy has origins going back over 60 years, but the modern market really began in the early 1990's, Paul-Emmanuel Goethals, co-founder of MEDraysintell, told HCB News. It really started accelerating around 2007-2008, around which time Varian Medical Systems entered the market and Mevion Medical Systems (then called Still River) introduced a compact system concept, he added.
Barring any significant shake-ups, MEDraysintell is predicting the market will continue downward an additional 25 percent by 2020.
Although it's been said that at least 10 percent of external radiotherapy patients could benefit from proton therapy, only 0.7 percent actually received it in 2018. Meanwhile, the majority of facilities in operation are not treating the maximum number of patients possible, with only 17 percent of proton facilities treating over 200 patients per treatment room.
"In 2018, two proton therapy facilities filed for bankruptcy," said Goethals, referring to Seattle Cancer Care Alliance Proton Therapy and ProCure Proton Therapy Center Oklahoma, "mainly because they were not able to attract a sufficient number of patients."
In order to reverse the trend, MEDraysintell recommends proton therapy stakeholders continue to publish research and expand the body of clinical evidence illustrating outcomes superior to conventional radiotherapy treatment. The group also called for stronger marketing so that more patients are referred to the treatment who stand to benefit.
The new report also indicates a market preference for single-room proton therapy facilities over multi-room. According to MEDraysintell, less than 40 percent of the facilities purchased in 2016 were single-room, whereas 2018 purchases were 100 percent oriented toward single rooms.
"A multi-room facility requires a larger investment, lets say, $150-200 million for a 4-5 room facility, but then the center needs to recruit a sufficient number of patients to 'fill' those rooms each year," said Goethals. "While a single-room facility would cost about $30-40 million, and you need to attract a lower number of patients to break even."
So, what does the future hold?
Currently, over 70 percent of proton therapy facilities are from just three vendors. Goethals anticipates "more than 10" vendors will eventually compete in the space, meanwhile consolidations will take place and hopefully the cost of equipment will start to trend downwards.
For more information on the proton therapy market forecast up to 2030, the full 350-page report and directory is available for purchase from MEDraysintell.